Sugi Predict

Sugi Predict / Compounds / SCHEMBL535688

SCHEMBL535688

SCHEMBL535688

O=C(NC(Cc1ccccc1)C(=O)O)c1cnccn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LONP1 P36776 12/20 0.71
▸ PSMB5 P28074 11/20 0.71
▸ PSMB8 P28062 10/20 0.71
▸ PSMB9 P28065 10/20 0.71
▸ PSMB6 P28072 10/20 0.71
▸ PSMB10 P40306 10/20 0.71
▸ PSMB11 A5LHX3 9/20 0.71
▸ PSMA7 O14818 9/20 0.71
▸ PSMB1 P20618 9/20 0.71
▸ PSMA1 P25786 9/20 0.71
▸ PSMA2 P25787 9/20 0.71
▸ PSMA3 P25788 9/20 0.71
▸ PSMA4 P25789 9/20 0.71
▸ PSMA5 P28066 9/20 0.71
▸ PSMB4 P28070 9/20 0.71
▸ PSMB3 P49720 9/20 0.71
▸ PSMB2 P49721 9/20 0.71
▸ PSMA6 P60900 9/20 0.71
▸ PSMA8 Q8TAA3 9/20 0.71
▸ PSMB7 Q99436 9/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535687 1.00 LONP1 (0.71) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL3926604 0.99 LONP1 (0.69) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL2127363 0.95 LONP1 (0.76) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL2127299 0.90 PSMB5 (0.69) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL2127921 0.90 PSMB5 (0.69) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL680573 0.90 LONP1 (0.68) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL8513905 0.90 PSMB5 (0.58) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL1688075 0.90 LONP1 (0.68) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL13078869 0.90 CTSL (0.71) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL2127762 0.89 PSMB5 (0.73) LONP1PSMB5PSMB8PSMB9PSMB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4008721-B1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARM INC (US) 2024-01-03 — — EP claimed
CN-114644682-A Preparation method of bortezomib 海南双成药业股份有限公司 2022-06-21 — — CN claimed
EP-3385267-B1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARM INC (US) 2021-09-29 — — EP claimed
CN-107474062-A The synthesis of the ester and acid compound of boron 千禧药品公司 2017-12-15 — — CN claimed
CN-106279355-A The preparation technology of bortezomib 北京博时安泰科技发展有限公司 2017-01-04 — — CN claimed
CN-103059054-A Synthetic method of bortezomib HANGZHOU PING HE AN KANG PHARMACEUTICAL CO LTD 2013-04-24 — — CN claimed
CN-102659919-A Synthetic method of bortezomib UNIV HEFEI TECHNOLOGY 2012-09-12 — — CN claimed
US-20230159471-A1 PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2023-05-25 — — US disclosed
US-20230159471-A1 PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2023-05-25 — — US disclosed
US-11584725-B2 Pyrazinoic acid conjugates and hybrid conjugates AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2023-02-21 — — US disclosed
CN-114644682-A Preparation method of bortezomib 海南双成药业股份有限公司 2022-06-21 — — CN disclosed
CN-110372612-B Preparation method of bortezomib derivative 西安都创医药科技有限公司 2021-06-25 — — CN disclosed
CN-110372613-B Preparation method of 2,3, 6-trisubstituted pyrazine nitroxide compound 江南大学 2020-09-04 — — CN disclosed
WO-2010114982-A2 LYOPHILIZATION CAKES OF PROTEASOME INHIBITORS CEPHALON, INC. (US) 2010-10-07 — — WO disclosed
US-20100226597-A1 BORTEZOMIB AND PROCESS FOR PRODUCING SAME DR. REDDY'S LABORATORIES LIMITED (IN) 2010-09-09 — — US disclosed
WO-2010089768-A2 PHARMACEUTICAL COMPOSITION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2010-08-12 — — WO disclosed
WO-2010089768-A2 PHARMACEUTICAL COMPOSITION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2010-08-12 — — WO disclosed
EP-2185159-A2 BORTEZOMIB AND PROCESS FOR PRODUCING SAME Dr. Reddy's Laboratories, Ltd. (IN) 2010-05-19 — — EP disclosed
WO-2009036281-A2 BORTEZOMIB AND PROCESS FOR PRODUCING SAME DR. REDDY'S LABORATORIES LTD. (IN) 2009-03-19 — — WO disclosed
CN-1960996-A Synthesis of boronic ester and acid compounds MILLENNIUM PHARM INC (US) 2007-05-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226597-A1 BORTEZOMIB AND PROCESS FOR PRODUCING SAME PSMC1, PSMB4, PSMB1 LONP1 505/4885PSMB5 10/4885PSMB8 11/4885
US-11584725-B2 Pyrazinoic acid conjugates and hybrid conjugates QPCT, RARA, PNKP LONP1 3776/4885PSMB5 2826/4885PSMB8 2924/4885
US-20230159471-A1 PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES QPCT, RARA, PNKP LONP1 3776/4885PSMB5 2826/4885PSMB8 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.